(S (NP (JJ Adverse) (NN drug) (NN reaction) (PRN (-LRB- -LRB-) (NP (NN ADR)) (-RRB- -RRB-))) (VP (VBZ is) (ADJP (RB widely) (JJ concerned) (PP (IN for) (NP (NML (JJ public) (NN health)) (NN issue))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBP propose) (NP (DT an) (JJ original) (NN approach)) (S (VP (TO to) (VP (VB detect) (NP (DT the) (NNS ADRs)) (S (VP (VBG using) (NP (NP (NN feature) (NN matrix)) (CC and) (NP (NN feature) (NN selection))))))))) (. .))
(S (NP (DT The) (NNS experiments)) (VP (VBP are) (VP (VBN carried) (PRT (RP out)) (PP (IN on) (NP (DT the) (NN drug) (NNP Simvastatin))))) (. .))
(S (S (NP (NP (JJ Major) (NN side) (NNS effects)) (PP (IN for) (NP (DT the) (NN drug)))) (VP (VBP are) (VP (VBN detected)))) (CC and) (S (NP (JJR better) (NN performance)) (VP (VBZ is) (VP (VBN achieved) (PP (VBN compared) (PP (IN to) (NP (JJ other) (JJ computerized) (NNS methods))))))) (. .))
(S (S (NP (DT The) (VBN detected) (NNS ADRs)) (VP (VBP are) (VP (VBN based) (PP (IN on) (NP (DT the) (JJ computerized) (NN method)))))) (, ,) (NP (JJ further) (NN investigation)) (VP (VBZ is) (VP (VBN needed))) (. .))
